Abstract: OBJECTIVE To evaluate the impact on total social costs for non-small cell lung cancer(NSCLC) patients with EGFR-mutation through a budget impact analysis, comparing the treatment strategy with and without afatinib(Giotrif^®) in the Chinese national reimbursement system, which would provide evidence for medical insurance decision makers. METHODS The budget impact model was constructed to assess the health care budgets changes in the 3 years (2018-2020) after afatinib was listed in Chinese national reimbursement system. RESULTS Compared with afatinib wasn't listed in health care system, total health care budgets in 3 years after afatinib was listed in would decrease by 36.44, 66.32, 96.20 million RMB, respectively. It would save 198.96 million RMB among 3 years. CONCLUSION The analysis suggests that the adoption of afatinib in the Chinese health care reimbursement list for the treatment of advanced NSCLC patients with EGFR-mutation will reduce the health care expenditure.